YCT-529, developed by US scientists, moves to early-stage phase 2 trial in New Zealand. Study published in Nature Communications showed it to be 99% effective in preclinical studies.

Industry animation and VFX studios are continue to announce hires from units of the former Technicolor, which collapsed in ...